Drug Trial Radar · NCT06627322
A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)
Last checked: Nov 20, 2026Latest source record: Apr 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
5,950
Planned (sponsor's estimate)
Start
Nov 21, 2024
Primary completion
Sep 30, 2029
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- Kyu Chang WonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Boryung Pharmaceutical Co., Ltd; Dong-A ST Co., Ltd.; HK inno.N Corporation; Daewoong Pharmaceutical Co. LTD.; Chong Kun Dang Pharmaceutical Corp.; Celltrion; Kakao Healthcare Corp.; Handok Inc.
- First posted
- Oct 4, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Glycemic control is a mainstay of diabetes management to reduce the risk of microvascular complications and cardiovascular outcomes in people with type 2 diabetes (T2D). However, intensive control to near-normal glycated hemoglobin (HbA1c) yielded complex results in previous landmark trials. Potential risks of intensive glycemic control, such as hypoglycemia and weight gain, may partly contributed to the possible harms associated with this approach. Recent advances in diabetes management with development of newer antidiabetic drugs which minimize possible harms of intensive glycemic control as well as reduce cardiorenal risks enabled safer glycemic reduction. Thus, this randomized trial aims to evaluate the effects of near normalization of HbA1c with novel approaches on microvascular complications and cardiovascular outcomes in people with T2D.
Conditions
- Type 2 Diabetes
Interventions
Dual-combination therapyDrug
Group 1: Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Any oral antiglycemic drugs on the market.
Triple-combination therapyDrug
Group 2: Metformin/SGLT2i/DPP-4i-based triple-cobmination therapy, or Group 3: Metformin/SGLT2i/Thiazolidinedione-based triple-cobmination therapy Any oral antiglycemic drugs on the market.
Dexcom G7, PastaDevice
Real-time continous glucose monitoring system (CGMS) Device (sensor): Dexcom G7 Device (software): Kakaohealthcare Pasta Barozen Fit is also available.
Primary outcomes
What the sponsor says the trial is designed to measure.
- A composite of major adverse cardiovascular events (MACE) or diabetic microvascular eventsTime frame: 6-month, 1-, 2-, 3-, 4-year after enrollment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Yeungnam University Medical Center
Daegu, South Korea · Not yet recruiting
Korea University Anam Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.